Delsys To Collaborate With PRI on Development of Accudep

Delsys Pharmaceutical Corporation (Princeton, NJ) will collaborate with the R.W. Johnson Pharmaceutical Research Institute (PRI; Raritan, NJ), a subsidiary of Johnson & Johnson (New Brunswick, NJ), to develop Delsys' novel Accudep technology. The technology will be used in the development and manufacture of solid oral dosage forms for a number of Johnson & Johnson's compounds.

In addition to the new collaboration, Delsys will receive an equity investment from Johnson & Johnson Development Corporation in conjunction with the collaboration. Under the terms of the agreement, Delsys will receive research and development support, milestone payments for multiple projects, and royalties on product sales. Additional terms of the agreement were not disclosed.

Delsys' Accudep technology is a highly controlled electrostatic powder deposition process that permits a drug's active ingredient to be deposited in precise quantities at high speed onto a variety of surfaces. Its specific benefits include: improved drug quality and safety, by minimizing excipients; reduced time to market, by enhancing flexibility in drug formulation; and an overall reduction in manufacturing costs, by supplanting the time-, labor-, and infrastructure-intensive process associated with traditional pharmaceutical manufacturing.

Delsys Pharmaceutical Corporation is a privately held company that uses its proprietary technology to enhance pharmaceutical development, manufacture, and drug delivery.

For more information: Martyn Greenacre, President & CEO, Delsys Pharmaceutical Corporation, 5 Vaughn Dr., Suite 305, Princeton, NJ 08540. Tel: 609-720-0033. Fax: 609-520-6692. Email: mgreenacre@delsyspharma.com.